38 hasil untuk "April Armstrong"
Menampilkan 1–20 · 0,74 detik · RSS
-
Artikel Jurnal Teks lengkap
Correction: Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010.
Juga tersedia di: PLOS
-
Artikel Jurnal Teks lengkap
Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010
Background: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade. Objectives: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for…
-
Artikel Jurnal
Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure
Abstract This narrative review evaluates the clinical evidence supporting brodalumab as a second-line therapy against moderate-to-severe plaque psoriasis in adults who have experienced prior systemic treatment failure. Despite advances in biologic therapy, treatment failure remains a substantial…
-
Artikel Jurnal
Increased pin diameter improves torsional stability in supracondylar humerus fractures: An experimental study
Abstract Background Pediatric supracondylar humerus fractures are the most common elbow fractures seen in children, and account for 16 % of all pediatric fractures. Closed reduction and percutaneous pin fixation is the current treatment technique of choice for displaced supracondylar fractures of…
-
Artikel Jurnal
The More Things Change, the More They Stay the Same
Introduction:. Despite increasing emphasis on the development and implementation of Residents-as-Teachers programs, resident perspectives on their roles as teachers have rarely been explored. This paper explores trends across 7 years of data collected from resident leaders across North American…
-
Artikel Jurnal
Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
Abstract While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents. It may therefore be beneficial for patients whose psoriasis fails to respond to one biologic to…
-
Artikel Jurnal
Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States
Background Topical treatments are the foundation for patients with psoriasis; however, adherence can be limited by patient preferences and treatment burden.Methods The Harris Poll conducted an online survey of US patients with psoriasis who use prescription topical therapy to examine their…
-
Artikel Jurnal
Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States
Abstract Introduction A survey was conducted by The Harris Poll on behalf of Arcutis Biotherapeutics in the USA to understand perspectives and burden of patients with psoriasis using prescription topical treatments for their disease. This manuscript presents results from the subset of patients with…
-
Artikel Jurnal
Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Abstract Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab. Effective, long-term treatments are needed, and head-to-head studies comparing these available therapeutics have yet to be conducted…
-
Artikel Jurnal
Dry Catheter Technique in Shoulder Arthroplasty
Introduction Interscalene regional anesthesia is effective for pain management but is not without complications. To determine whether postoperative neurologic findings were related to the surgery versus the regional catheter, we developed the dry catheter technique where patients could be examined…
-
Artikel Jurnal
The most effective corticosteroid dose in the treatment of glenohumeral osteoarthritis: Feasibility pilot and protocol for double blinded randomized controlled trial
Objective: Osteoarthritis affects over 5.4 million people in the United States. A common treatment is to perform intra-articular corticosteroid injections. However, the ideal steroid dose is unknown. This study aimed to pilot a corticosteroid injection protocol for primary glenohumeral OA. Methods…
-
Artikel Jurnal
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and…
-
Artikel Jurnal
Metformin does not decrease the incidence of shoulder arthroplasty in patients with glenohumeral joint osteoarthritis
Background: Metformin is an antidiabetic medication that is routinely prescribed. Recent reports suggest a dose-response disease-modifying effect on osteoarthritis (OA) of the knee with patients on metformin having a lower incidence of total knee arthroplasty. However, it is unknown whether this…
-
Artikel Jurnal
Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies
Abstract Introduction Psoriasis ranges from mild to severe with the majority of patients having mild disease. Mild to moderate disease is often treated with topical therapies while photo-, oral, and biologic therapies are generally reserved for moderate-to-severe disease. There is a strong…
-
Artikel Jurnal
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis
Abstract Introduction Biologic treatments have made complete skin clearance in moderate to severe plaque psoriasis a real possibility. Although clinical trials demonstrated the superiority of bimekizumab over secukinumab, adalimumab, and ustekinumab, direct comparisons with other biologics are not…
-
Artikel Jurnal
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification
…moderate-to-severe plaque psoriasis who initiated risankizumab between April 2019 and August 2023 and were treated for 12 (± 3) months were identified from the CorEvitas Psoriasis Registry and stratified by baseline BSA. At 12 months, skin clearance was assessed by achievement of Psoriasis Area…
-
Artikel Jurnal
Telemedicine and psoriasis: A review based on statements of the telemedicine working group of the International Psoriasis Council
Abstract During the past few decades, classical in‐person communication has been enriched by opportunities for telemedicine. We are in a learning healthcare environment that takes advantage of the opportunities of telemedicine and in‐person consultations, reconciling the individuality of the…
-
Artikel Jurnal
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
In the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52…